Results 151 to 160 of about 9,651 (201)

Real-life experience with a "modified-MEMMAT" regimen for relapsed medulloblastoma. [PDF]

Ther Adv Med Oncol
Cacchione A, Del Baldo G, D'Antonio F, Di Ruscio V, Megaro G, Pilotto C, Tornesello A, Cocciolo A, Vennarini S, Chiesa S, Carai A, De Salvo A, Albino G, Colafati GS, Slavc I, Mastronuzzi A.   +15 more
europepmc   +1 more source

Editorial: Targeting major human fungal pathogens: novel insights into virulence and antifungal therapies. [PDF]

Front Cell Infect Microbiol
Sun T, Li H, Zhang Y.
europepmc   +1 more source

Development of multitarget drugs from l-3-n-butylphalide and the derivatives

Archives of Pharmacy Practice, 2012
Wang Xiaoliang,
doaj  

Special Issue "Natural Products as Multitarget Agents in Human Diseases". [PDF]

Int J Mol Sci
Marchev AS, Mihaylova NM.
europepmc   +1 more source

Marine-Derived Defenses Against HIV: Emerging Bioactive Molecules from the Seas. [PDF]

Mar Drugs
Santos T, Pintão A, Marques CS, Brandão P.   +3 more
europepmc   +1 more source

The Necessity for Polypharmacological Research - An Editorial on 'Network Polypharmacology of ATP-binding Cassette (ABC) and Solute Carrier (SLC) Transporters'. [PDF]

Front Pharmacol
Rafehi M, Juvale K, Pulaski L, Stefan SM.   +3 more
europepmc   +1 more source

A Hybrid In Silico Approach for Identifying Dual VEGFR/RAS Inhibitors as Potential Anticancer and Anti-Angiogenic Agents. [PDF]

Pharmaceuticals (Basel)
Bono A, La Monica G, Alamia F, Tocco D, Lauria A, Martorana A.   +5 more
europepmc   +1 more source

Network pharmacology: Changes the treatment mode of "one disease-one target" in cancer treatment.

World J Gastrointest Oncol
Liu S, Yu YW.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Designing Approaches to Multitarget Drugs

Methods and Principles in Medicinal Chemistry, 2017
Plexxikon adopted a fragment-based drug discovery strategy for the design of multitarget drugs that represents an evolution of the procedure followed for the discovery of a family of selective phosphodiesterase (PDE) inhibitors. The fragment-based drug design was successfully applied for the discovery of multitarget protein-protein interaction ...
Luca Costantino
exaly   +2 more sources